Your browser doesn't support javascript.
loading
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Zhang, Yi; Zhou, Hu; Duan, Minghui; Gao, Sujun; He, Guangsheng; Jing, Hongmei; Li, Junmin; Ma, Liangming; Zhu, Huanling; Chang, Chunkang; Du, Xin; Hong, Mei; Li, Xin; Liu, Qingchi; Wang, Wei; Xu, Na; Yang, Haiping; Lu, Binhua; Yin, Hewen; Wu, Liqing; Suo, Shanshan; Zhao, Qingwei; Xiao, Zhijian; Jin, Jie.
Afiliación
  • Zhang Y; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
  • Zhou H; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
  • Duan M; Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China.
  • Gao S; Zhejiang University Cancer Center, Hangzhou, People's Republic of China.
  • He G; Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Jing H; Department of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Beijing, People's Republic of China.
  • Li J; Department of Hematology, The First Hospital of Jilin University, Changchun, People's Republic of China.
  • Ma L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalize, Jiangsu, People's Republic of China.
  • Zhu H; Department of Hematology, Peking University Third Hospital, Beijing, People's Republic of China.
  • Chang C; Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University Medical School, Shanghai, People's Republic of China.
  • Du X; Department of Hematology, Shanxi Bethune Hospital, The Third Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
  • Hong M; Department of Hematology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
  • Li X; Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China.
  • Liu Q; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Wang W; Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  • Xu N; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
  • Yang H; Department of Hematology, The First Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
  • Lu B; Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
  • Yin H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
  • Wu L; Department of Hematology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, People's Republic of China.
  • Suo S; Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, People's Republic of China.
  • Zhao Q; Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, People's Republic of China.
  • Xiao Z; Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, People's Republic of China.
  • Jin J; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Am J Hematol ; 98(10): 1588-1597, 2023 10.
Article en En | MEDLINE | ID: mdl-37470365
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mielofibrosis Primaria / Inhibidores de las Cinasas Janus Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Am J Hematol Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mielofibrosis Primaria / Inhibidores de las Cinasas Janus Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Am J Hematol Año: 2023 Tipo del documento: Article